FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.Key topics discussed include:•⁠  ⁠The mechanism of action of Zolbetuximab and its target, Claudin 18.2.•⁠  ⁠An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).•⁠  ⁠Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.•⁠  ⁠The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.•⁠  ⁠Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!YouTube: https://youtu.be/BfpDHpqgHMsFollow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers